Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Northwest Biotherapeutics (NWBO) Non-Current Debt (2016 - 2025)

Historic Non-Current Debt for Northwest Biotherapeutics (NWBO) over the last 16 years, with Q3 2025 value amounting to $7.2 million.

  • Northwest Biotherapeutics' Non-Current Debt fell 6526.7% to $7.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $7.2 million, marking a year-over-year decrease of 6526.7%. This contributed to the annual value of $12.4 million for FY2024, which is 3897.2% down from last year.
  • Northwest Biotherapeutics' Non-Current Debt amounted to $7.2 million in Q3 2025, which was down 6526.7% from $9.2 million recorded in Q2 2025.
  • Northwest Biotherapeutics' Non-Current Debt's 5-year high stood at $25.2 million during Q4 2021, with a 5-year trough of $5.9 million in Q3 2022.
  • For the 5-year period, Northwest Biotherapeutics' Non-Current Debt averaged around $13.8 million, with its median value being $12.4 million (2024).
  • Its Non-Current Debt has fluctuated over the past 5 years, first soared by 29063.98% in 2021, then tumbled by 7618.46% in 2022.
  • Over the past 5 years, Northwest Biotherapeutics' Non-Current Debt (Quarter) stood at $25.2 million in 2021, then crashed by 76.18% to $6.0 million in 2022, then soared by 239.04% to $20.3 million in 2023, then tumbled by 38.97% to $12.4 million in 2024, then crashed by 42.01% to $7.2 million in 2025.
  • Its last three reported values are $7.2 million in Q3 2025, $9.2 million for Q2 2025, and $7.1 million during Q1 2025.